OncoMethylome Sciences to Collaborate with GlaxoSmithKline Biologicals for Personalized Cancer Treatment

27-Nov-2007

Automated high-throughput cell counting for maximum efficiency and precision

High-performance hybrid silica for preparative chromatography

Robust and versatile: The workhorse microplate reader for the life sciences

OncoMethylome Sciences announced that it has entered into a collaboration with GlaxoSmithKline (GSK) Biologicals. The goal of the collaboration is to develop DNA methylation biomarkers for use in the personalization of cancer treatment with certain immunotherapeutics in development by GSK Biologicals.

"We look forward to using our high-throughput platform to efficiently test our portfolio of methylation biomarkers on clinical samples provided by GSK Biologicals. We are pleased that GSK Biologicals has chosen OncoMethylome for this collaboration" commented Dr. Jim DiGuiseppi, Chief Technology Officer of OncoMethylome.

The collaboration is supported by a Wallonia (BioWin) research grant that was announced in April of this year. Further financial details of the agreement were not disclosed.

https://www.bionity.com/en/news/74938/oncomethylome-sciences-to-collaborate-with-glaxosmithkline-biologicals-for-personalized-cancer-treatment.html